Full-Time
Manager Data Management
Goodwin
1,001-5,000 employees
Global law firm handling complex transactions
Compensation Overview
$160k - $185k/yr
Boston, MA, USA + 7 more
More locations: Santa Monica, CA, USA | Washington, DC, USA | San Francisco, CA, USA | Los Angeles, CA, USA | Philadelphia, PA, USA | New York, NY, USA | United States
In Person
Bachelor's
 Data & Analytics (1) |
|---|
Get referred to Goodwin
See people who can refer or advise you
- A Bachelor's degree or equivalent combination of education and experience is required.
- At least seven years of experience in data management, data quality, data governance, or data stewardship roles is required.
- Experience defining and implementing data quality metrics, key performance indicators, and performance reporting is required.
- Demonstrated experience building or operationalizing data quality or data management programs is required.
- Strong knowledge of master data management, data quality frameworks, and distributed data ownership models is required.
- Advanced Microsoft Excel skills and familiarity with SQL and customer relationship management systems, such as Microsoft Dynamics and Salesforce, are required.
- Strong analytical, problem-solving, and communication skills are required.
- Own and lead the firm's data quality and master data management program across designated data domains.
- Establish, enforce, and continuously improve data quality standards, key performance indicators, and service-level agreements, including completeness, accuracy, timeliness, and consistency.
- Define and implement a clear data ownership model, including responsibility assignment matrices for data owners, stewards, and supporting teams.
- Drive accountability for data quality by partnering with business stakeholders and enforcing adherence to defined standards and performance expectations.
- Develop and maintain data quality scorecards and reporting to provide transparency into performance at the team, domain, and firm level.
- Manage and prioritize data quality remediation efforts, including root-cause analysis and implementation of sustainable corrective actions.
- Serve as the escalation point for complex or cross-functional data issues, including non-compliance with data standards or service-level agreement breaches.
- Partner with Data Governance to align on policies and controls while independently driving operational execution and compliance.
- Oversee bulk data updates, audits, exception handling, and data correction processes with a focus on scalability and control.
- Drive process improvements, automation opportunities, and tooling enhancements related to data quality and data management operations.
- Supervise, coach, and provide day-to-day direction to data management staff.
- Ensure documentation of data standards, definitions, processes, and controls is current and maintained.
- Experience operating in a federated or distributed data ownership environment.
- Experience influencing business stakeholders and driving accountability without direct authority.
- Familiarity with data governance tools, data catalogs, and data quality platforms.
Goodwin is a global law firm providing advisory, transactional, and litigation services to businesses across industries such as financial services, life sciences, private equity, real estate, and technology. It works by assembling senior legal teams to handle complex deals, disputes, and compliance across its offices in the US, Europe, and Asia. Its differentiator is its scale and international reach, enabling cross-border support and industry-specific guidance. The firm's goal is to help clients navigate complex legal landscapes, protect their interests, and achieve business objectives through practical, client-focused legal solutions.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Boston, Massachusetts
Founded
1912
Get referred to Goodwin
See people who can refer or advise you
Simplify's Take
What believers are saying
- Goodwin posted record 2025 revenue of $2.72 billion, up 11.2%.
- San Diego hires in July 2026 strengthened life sciences IP and litigation coverage.
- Its AI tool launched in August 2026, targeting faster venture financings and broader workflows.
What critics are saying
- June 2026 lateral raids took two Goodwin private equity partners to Willkie.
- Morgan Lewis hired former London co-head Gemma Roberts in June 2026.
- If partner attrition persists, Goodwin’s elite platform loses pricing power and client control.
What makes Goodwin unique
- Goodwin’s industry-built platform combines life sciences, private equity, real estate, and technology.
- The firm holds 71 of PERE’s top 100 real estate managers as clients.
- Goodwin is embedding AI with a $25 million annual internal product investment.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Wellness Program
Employee Discounts
Company News
Goodwin bolsters Real Estate funds platform with addition of Rebecca Lock. Professionals Global law firm Goodwin today announced that Rebecca (Becca) Lock has joined the firm as partner in its Real Estate and Investment Funds and Capital industry groups in the Philadelphia office. "Becca is a highly regarded advisor to real estate fund sponsors, with strong experience across fund formation, raising capital, and complex investment structures," said John Ferguson, leader of Goodwin's Investment Funds and Capital industry group. "Her arrival will further strengthen our market-leading position in the real estate funds market and enhance our ability to advise sponsors and investors on sophisticated transactions. We are delighted to welcome Becca to the firm." Becca focuses on structuring, negotiating, and forming real estate funds and their management companies. She advises global real estate and private equity fund sponsors on establishing open-end and closed-end investment funds, vehicles, and accounts, including programmatic joint ventures and co-investment arrangements. Beyond fund formation, Becca's experience includes complex private equity transactions such as key person events, strategic investments in fund sponsors, minority stake sales, secondaries, seed capital, and anchor investor arrangements. Becca's arrival builds on Goodwin's continued investment in its market-leading Investment Funds and Capital platform, following the recent additions of partners Julia Kolovarsky, Olya Kurilovich, and Daniel Mencaroni in New York. With lawyers across Europe, Asia, and the United States, Goodwin's global Investment Funds and Capital and Real Estate teams advise investment managers, sponsors, and investors on the structuring, raising, financing, and deployment of capital across global markets. Drawing on more than 50 years of experience in fund structuring and deep real estate market knowledge, the firm represents more than 1,000 investment managers worldwide on funds ranging from less than $10 million to more than $25 billion. Goodwin counts 71 of private equity real estate's (PERE) top 100 real estate investment managers among its clients. Goodwin advises across a broad range of strategies, with a special focus in private equity, real estate, technology, and life sciences, and provides integrated counsel spanning private fund formation, acquisitions and dispositions, REITs, M&A, financings, and other complex investment structures. The firm's strength in these practices have earned recognition from Chambers Global, Private Equity International, PERE, and U.S. News - Best Lawyers, including honors for fund formation and real estate fund formation.
FisherBroyles adds veteran intellectual property partners in Atlanta and Boston. W. Scott Creasman and Suzanne Nguyen strengthen firm's IP platform. ATLANTA - FisherBroyles, LLP, the world's first and one of the largest distributed law firms, has added to its roster of partners veteran intellectual property attorneys W. Scott Creasman in Atlanta and Suzanne Nguyen, Ph.D., in Boston. Together, Creasman and Nguyen further expand the firm's nationally recognized IP practice, bringing decades of experience advising clients across the full lifecycle of innovation, from patent strategy and portfolio development to trademark protection, licensing and intellectual property litigation. Creasman joins FisherBroyles' IP group after serving as partner with Taylor Duma LLP since 2007. He also spent nearly 17 years with Powell Goldstein LLP prior to its 2009 merger with Bryan Cave LLP, now BCLP. His practice encompasses IP and technology litigation, as well as trademark and copyright prosecution, licensing and brand management. He advises clients on matters involving patents, trademarks, copyrights, trade dress, trade secrets, false advertising and e-commerce issues, including domain name disputes, privacy, information security and website accessibility. Creasman also represents clients in the education, entertainment and sports industries, including professional sports organizations, media companies, publishers and technology businesses. Licensed in Georgia since 1990, Creasman has been recognized as Martindale-Hubbell AV(R) Preeminent(TM), The Best Lawyers in America(R), Georgia Trend's Legal Elite and Georgia Super Lawyers. He earned his bachelor's degree from Yale University before graduating from Duke University School of Law. Nguyen joins the firm's Boston office from Goodwin Procter LLP. She previously practiced with McDermott Will & Emery LLP and Choate Hall & Stewart LLP and brings nearly two decades of IP experience serving emerging life sciences companies, investors and innovative healthcare businesses. She focuses on strategic patent counseling and prosecution for biotechnology and life sciences clients, helping companies build and grow valuable patent portfolios while supporting financings, strategic partnerships and M&A transactions. Her experience spans a broad range of cutting-edge technologies, including antibody and peptide therapeutics, gene therapy, gene editing, radiopharmaceuticals, immuno-oncology, cell therapies, epigenetics, diagnostics and synthetic biology. She also has prior in-house experience as a global patent advisor with Mölnlycke Health Care AB. Nguyen earned her J.D. from Boston University School of Law, a Ph.D. from the Massachusetts Institute of Technology, and a bachelor's degree from the California Institute of Technology. She is admitted to practice in Massachusetts and before the U.S. Patent and Trademark Office. She has been recognized as a Massachusetts Rising Star by Super Lawyers from 2023 through 2026. "Scott and Suzanne significantly strengthen our already robust intellectual property platform," said James Fisher II, cofounder and managing partner of FisherBroyles. "Scott's decades of experience in intellectual property litigation, trademark prosecution and technology transactions, combined with Suzanne's deep scientific background and sophisticated life sciences patent practice, further enhance our ability to serve innovative companies, investors and entrepreneurs across the country. We continue to attract exceptional talent, and Scott and Suzanne are outstanding additions to our growing national IP team." The additions of Creasman and Nguyen reflect FisherBroyles' continued investment in expanding its nationally recognized intellectual property practice and serving innovative clients across key markets. FisherBroyles was founded in 2002 by Fisher and Kevin Broyles. About FisherBroyles, LLP Founded in 2002, FisherBroyles, LLP is the first and one of the world's largest distributed law firm partnerships. The Next Generation Law Firm(R) has grown to hundreds of partners practicing in 32 markets globally. The FisherBroyles' efficient and cost-effective Law Firm 2.0(R) model leverages talent and technology instead of unnecessary overhead that does not add value to its clients, all without sacrificing BigLaw quality. Visit its website at http://www.fisherbroyles.com/ to learn more about its firm's unique approach and how Legal Reader can best meet your legal needs.
Goodwin Procter unveils AI-enhanced tool for venture capital funding. August 14, 2026, 1:31 pm CDT Goodwin Procter's new proprietary artificial intelligence tool is the first to come from its multimillion dollar investment into developing a series of planned programs designed to help its lawyers work more efficiently. (Image from Shutterstock) Goodwin Procter has unveiled its own artificial intelligence tool for venture capital financing. Bloomberg Law reported Thursday that the tool is the first of several planned AI programs developed internally at the Am Law 100 law firm. The firm plans to invest $25 million per year to create products "designed by lawyers and powered by technology with a real client focus," Anthony McCusker, the firm's chair, told Bloomberg Law. The financing tool is powered by a custom version of Anthropic's Claude platform and will provide the basis for programs in other practice areas, including mergers and acquisitions, private equity, litigation and fund formation, McCusker told Bloomberg Law. Bloomberg law added that the tool was developed under the leadership of Eric Tan, chief digital and technology officer at the firm and was built by six associates. The firm hopes to save its lawyers a million hours worth of work per year, which equates to about 1.5 hours per day for Goodwin's nearly 3,000 attorneys and business professionals, according to Bloomberg Law. Discover more Legal Education Attorney Referral Service Legal News Subscription
Holland & Knight strengthens public company, M&A and Korea practices with addition of Jean Lee in Newport Beach. NEWPORT BEACH, Calif. (August 11, 2026) - Holland & Knight continues to expand its Corporate, M&A and Securities practice in California with the addition of Jean Lee as a partner in the Firm's Newport Beach office. A highly regarded cross-border M&A attorney, Ms. Lee will also play a key role in the Firm's Korea Practice, further strengthening its ability to advise Korean and multinational clients on sophisticated domestic and international transactions. Prior to joining Holland & Knight, Ms. Lee was a partner at Goodwin Procter. Ms. Lee represents public and private companies, as well as private equity funds, in a broad range of corporate matters, including mergers and acquisitions, going private transactions, divestitures and corporate governance. She has developed long-standing relationships with clients across the technology, life sciences, and automotive-semiconductor sectors as well as a number of the top financial advisors who are active in these industries. In addition, Ms. Lee's arrival further strengthens Holland & Knight's market-leading Korea Practice, expanding the Firm's capabilities in advising Korean and international clients on high-value cross-border mergers and acquisitions, strategic investments and other transformative corporate transactions. Combined with Holland & Knight's deep bench of lawyers serving clients across Korea, the United States and key global markets, her arrival reinforces the Firm's commitment to delivering seamless, cross-border counsel for clients pursuing opportunities in one of the world's most dynamic economies. Ms. Lee's addition to the platform comes on the heels of a flurry of hires in California and across the country. In the last two months, the Firm has added Partner David Jargiello in San Francisco as well as Partners Jessica Berkowitz in Dallas, Monica Kwok and David Powers in Boston, and Aaron Russ in Richmond. "Jean is a highly trained M&A attorney whose experience at leading corporate practices has exposed her to sophisticated private equity, strategic and public company transactions, including complex take-private matters and other high-value M&A engagements," said Stephen Dietrich, practice group leader of Holland & Knight's Corporate, M&A and Securities Section in the Central/West Region. "She is exceptionally well-suited to support our sponsor-backed clients and manage complex deal execution, and we are excited about the role she will play in expanding our private equity M&A capabilities on the West Coast." "Jean will further enhance our capability to execute M&A and capital markets transactions for Korean public and private companies, private equity and hedge funds, asset managers and government sponsored entities across the technology, energy, automotive and other industries," said David Cole, Holland & Knight's Korea Practice Chair. "Korean investor appetite for high quality U.S. assets continues to grow rapidly notwithstanding recent tariff stability, and Jean will provide Korean investors with years of insight, experience and judgment exercising market recognized transactions throughout the U.S." "Holland & Knight's standing as one of the most active firms in the M&A and private equity space gives me an exceptional platform to continue advising public and private companies and private equity funds," said Ms. Lee. "I'm excited to bring my experience to Holland & Knight and to collaborate with colleagues across the Firm's practices to deliver seamless service on our clients' transactions, while contributing to the continued growth of the Firm's Korea Practice Team." Ms. Lee earned a J.D. degree from USC Gould School of Law, a M.B.A. degree from the University of Southern California and a B.S. degree from the University of California, Berkeley. Recently recognized as the Private Equity Law Firm of the Year by the Global M&A Network and M&A Law Firm of the Year by M&A Advisor, Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG, Mergermarket, PitchBook and The Deal. Through the HK Deal Flow(SM) program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors. Related practices. Related office. Media Contacts Efrain Avila-Martinez
NueCell Bio announces its launch as a new translational partner for cell therapies with unique expertise to accelerate treatments from discovery into GMP manufacturing. Aug 05, 2026, 03:00 ET SAN DIEGO, Aug. 5, 2026 /PRNewswire/ - NueCell Bio, a newly established cell therapy science and development services company that utilizes proprietary modular translational development solutions focused on advancing modern cell therapies from scientific discovery through clinical readiness, today announced its launch as a specialist partner uniquely positioned to advance and accelerate cell-based treatments to patients. NueCell Bio is led by a team possessing unprecedented experience in the advanced therapies market. The team's industry-leading expertise in supporting customers developing novel cell therapies positions NueCell Bio to offer customizable modular technologies to engineer cells and develop scalable, GMP-ready manufacturing processes and analytics for a wide range of cell therapies. NueCell Bio works across a broad spectrum of groundbreaking science in this field, including CAR-T, stem cells, iPSC-derived therapies, gene-edited cells, and tissue repair platforms - supporting both autologous and allogeneic products. NueCell Bio is headquartered in the Sorrento Valley area of San Diego - a leading hub for biotechnology and advanced therapy development - in a 26,300 square-foot, state-of-the-art facility that specializes in translational services for cell therapy. "Advanced therapies, including cell therapies, are expanding rapidly across the United States, Europe, Japan, South Korea, and emerging biotechnology markets," said Michael Wourms, Chief Executive Officer of NueCell Bio. "The industry does not suffer from a shortage of scientific breakthroughs, it suffers from a difficulty in efficiently converting these breakthroughs into therapies that can be evaluated, manufactured, and ultimately delivered to patients. That translational phase is where NueCell Bio is focused. By combining NueCell's flexible and modular translational development solutions with scientific expertise, analytical capabilities, and a proven track record, we believe we are uniquely positioned to help innovators advance the next generation of cellular therapies for cancer, immune-mediated diseases, tissue repair and regeneration, and other areas of significant unmet medical need." "NueCell Bio is distinctively positioned to advance cell therapies from early discovery through clinical development," said Dr. Uma Lakshmipathy, Co-founder and Chief Science Officer. "Cell therapies have been proven to work and are commercially available, but manufacturing them at scale is still slow and expensive, largely because each therapy is biologically unique. The most promising therapies often face the greatest development complexity. Every program follows a different path, and the scientific, analytical, and development challenges that create risk for one company may be very different for another. Our role is to understand where each program is today, identify what is needed to move it forward, and apply the right expertise and resources at the appropriate time to help accelerate its path towards clinical readiness. By combining modular technology stacks of scientific, analytical, process development, and manufacturing-enabling capabilities, NueCell Bio is uniquely positioned to help innovators navigate critical development challenges and advance promising therapies more efficiently to reach patients faster." Renowned University of Pennsylvania Professor, Dr. Bruce Levine, a member of NueCell Bio's Scientific Advisory Board, said, "The ecosystem of advanced therapies I have been part of for many years is moving rapidly and NueCell Bio helps meet the demand by supporting the development of life-altering and life-saving treatments that were previously only a distant hope in many challenging areas of medicine. To reach more patients, the future of cell therapy lies in expanding beyond oncology towards additional broad indications, while still addressing low-incidence diseases. To support this goal, the incorporation of precision engineering, efficient manufacturing processes and advanced analytics is essential." "The ability to genetically engineer cells to have the characteristics to treat specific diseases is key, but another very important aspect is successfully advancing these programs from lab research into a GMP manufacturing process that is capable of consistently delivering cells in sufficient quantities and with required characteristics and viability," said Dr. Gabor Veres, a member of NueCell Bio's Scientific Advisory Board. "With the expertise of our team and state-of-the-art capabilities, NueCell Bio is well positioned to support customers by developing reliable, consistent and scalable processes suited to clinical manufacturing and future commercialization." Addressing the acquisition and the future, Dr. Richard Snyder, Chair of the Board and Co-founder of NueCell Bio, said, "I am incredibly excited by how this business brings together such an extraordinary caliber of leaders in the field, along with the team and assets transitioning to NueCell Bio. Beyond this, our team's significant industry networks are an equally strong factor in establishing NueCell as a highly differentiated cell therapy services business positioned to address the needs of current and future customers." In connection with the transaction, Kineticos Life Sciences served as exclusive advisor to NueCell Bio, with Goodwin Procter LLP serving as legal counsel. About NueCell Bio NueCell Bio is a San Diego-based company that works with academic institutions, biotechnology companies and pharmaceutical companies to advance cell therapies from concept and early research into clinical development. Our team brings deep expertise in biology, cell engineering, bioprocessing, and advanced technology integration, supported by modular technology stacks that can be tailored to each program. NueCell Bio gives clients access to experienced design, development and CMC expertise. By combining scientific excellence, strong quality systems, scalable operations, and 'customer-first' engagement, NueCell Bio helps accelerate the journey from scientific discovery to clinical delivery. For more information, visit www.NueCellBio.com Media contact: